Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maxine Giannotti"'
Autor:
Ian E. Krop, Warren P. Mason, Samuel C. Blackman, Tina Guthrie, Andrey Loboda, Cong Chen, Morris D. Groves, Steven J. Freedman, Maxine Giannotti, Jared Lunceford, Robert A. Beckman, Prakash Chinnaiyan, Santosh Kesari, Jeremy Hing, Patricia LoRusso, Tim Demuth, James Watters, Alexei A. Podtelezhnikov, Nicholas Butowski, Patrick Y. Wen
Publikováno v:
Journal of Clinical Oncology. 30:2307-2313
Purpose Aberrant Notch signaling has been implicated in the pathogenesis of many human cancers. MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required for Notch pathway activation. Safety, maximum-tolerated dose, pharmacokinetics (PK
Autor:
Maxine Giannotti, Xiaoyun Li, Peter Hersey, Adil Daud, Richard F. Kefford, Anthony M. Joshua, Roxana S. Dronca, Amita Patnaik, Kevin Gergich, Soonmo Peter Kang, Tara C. Gangadhar, F.S. Hodi, Jill A. Lindia, Scot Ebbinghaus, Omid Hamid, Hassane M. Zarour, Antoni Ribas, Caroline Robert, Jeffrey S. Weber, W. Hwu, Jedd D. Wolchok
Publikováno v:
European Journal of Cancer. 51:e24
Background Pembrolizumab is a potent humanised monoclonal antibody against PD-1 that has shown efficacy and safety in patients with advanced solid tumours and haematological malignancies. Methods KEYNOTE-001 (NCT01295827) was a multicohort phase 1 st
Autor:
Tara C. Gangadhar, Wen-Jen Hwu, Maxine Giannotti, Adil Daud, Jeffrey S. Weber, Richard W. Joseph, Caroline Robert, Richard F. Kefford, Omid Hamid, Soonmo Peter Kang, F. Stephen Hodi, Scot Ebbinghaus, Amita Patnaik, Roxana S. Dronca, Anthony M. Joshua, Hassane M. Zarour, Antoni Ribas, Jedd D. Wolchok, Peter Hersey, Xiaoyun Nicole Li
Publikováno v:
Journal of Clinical Oncology. 33:9050-9050
9050 Background: The anti–PD-1 antibody pembro is approved in the US for treating advanced MEL that progressed following IPI and, if BRAFV600 mutant, a BRAF inhibitor. Immune-related AEs (irAEs) ar...
Autor:
Soonmo Peter Kang, Hassane M. Zarour, F.S. Hodi, Jill A. Lindia, Scot Ebbinghaus, Amita Patnaik, W. Hwu, Tara C. Gangadhar, Caroline Robert, Omid Hamid, Anthony M. Joshua, Adil Daud, Antoni Ribas, Y. Ge, Jedd D. Wolchok, Richard F. Kefford, Peter Hersey, Jeffrey S. Weber, Maxine Giannotti, Roxana S. Dronca
Publikováno v:
Annals of Oncology. 25:v1
Aim: Pembro has demonstrated strong antitumor activity in patients (pts) with advanced MEL at doses of 10 mg/kg every 2 weeks (Q2W), 10 mg/kg Q3W, and 2 mg/kg Q3W. Previous randomized data from KEYNOTE-001 showed no difference in efficacy or safety b